Skip to main content

Table 2 Summary of efficacy outcomes

From: S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial

 

ITT population ( n= 49)

Endpoints

n

(%)

pCR* in breast and AXLN

11

(22.5%)

pCR* in breast

15

(30.6%)

Clinical response

  

   Complete response

6

(12.3)

   Partial response

27

(55.1)

   Stable disease

14

(28.6)

   Progressive disease

1

(2.0)

   Non-assessable

1

(2.0)

Breast-conserving surgery

  

   Yes

21

(42.9)

   No

26

(53.1)

   Non-assessable

2

(4.0)

  1. ITT, intent-to-treat; pCR, pathological complete response; *pCR was defined as the absence of invasive disease.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us